Genetic and Epigenetic Regulation of Aortic Aneurysms

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Kim, Ha Won ^a   Stansfield, Brian K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNTRANSLATED RNA; LIPID; TRANSFORMING GROWTH FACTOR BETA;

ABDOMINAL AORTA ANEURYSM; AGING; AORTA ANEURYSM; DISEASE ASSOCIATION; DNA MODIFICATION; EPIGENETICS; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; INFLAMMATION; LIPID METABOLISM; REVIEW; RISK FACTOR; SMOKING; THORACIC AORTA ANEURYSM; AGED; AORTA RUPTURE; BIOLOGICAL MODEL; CHEMISTRY; DISEASE COURSE; DNA SEQUENCE; EXTRACELLULAR MATRIX; FEMALE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; MALE; MARFAN SYNDROME; METABOLISM; MUTATION; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE; THORACIC AORTA;

AGED; AGING; AORTA, THORACIC; AORTIC ANEURYSM, ABDOMINAL; AORTIC ANEURYSM, THORACIC; AORTIC RUPTURE; DISEASE PROGRESSION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LIPIDS; MALE; MARFAN SYNDROME; MODELS, GENETIC; MUSCLE, SMOOTH; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SMOKING; TRANSFORMING GROWTH FACTOR BETA;

EID: 85010370184     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/7268521     Document Type: Review

References (168)

1. N. L. Weintraub, "Understanding abdominal aortic aneurysm," The New England Journal of Medicine, vol. 361, no. 11, pp. 1114-1116, 2009.
2. J. A. Cowan Jr., J. B. Dimick, P. K. Henke, J. Rectenwald, J. C. Stanley, and G. R. Upchurch Jr., "Epidemiology of aortic aneurysm repair in the United States from 1993 to 2003," Annals of the New York Academy of Sciences, vol. 1085, pp. 1-10, 2006.
3. A. Wanhainen, K. Mani, and J. Golledge, "Surrogate markers of abdominal aortic aneurysm progression," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 36, no. 2, pp. 236-244, 2016.
4. G. Albornoz, M. A. Coady, M. Roberts et al., "Familial thoracic aortic aneurysms and dissections-incidence, modes of inheritance, and phenotypic patterns," Annals of Toracic Surgery, vol. 82, no. 4, pp. 1400-1405, 2006.
5. H. C. Dietz, C. R. Cutting, R. E. Pyeritz et al., "Marfan syndrome caused by a recurrent de novo missense mutation in the fbrillin gene," Nature, vol. 352, no. 6333, pp. 337-339, 1991.
6. L. Faivre, A. Masurel-Paulet, G. Collod-Beroud et al., "Clinical and molecular study of 320 children with marfan syndrome and related type I fbrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations," Pediatrics, vol. 123, no. 1, pp. 391-398, 2009.
7. S. A. LeMaire, M.-L. N. McDonald, D.-C. Guo et al., "Genome-wide association study identifes a susceptibility locus for thoracic aortic aneurysms and aortic dissections spanning FBN1 at 15q21.1," Nature Genetics, vol. 43, no. 10, pp. 996-1000, 2011.
8. G. Collod-Béroud, S. Le Bourdelles, L. Ades et al., "Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database," Human Mutation, vol. 22, no. 3, pp. 199-208, 2003.
9. B. L. Loeys, J. Chen, E. R. Neptune et al., "A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2," Nature Genetics, vol. 37, no. 3, pp. 275-281, 2005.
10. A. F. Baas, J. Medic, R. van 't Slot et al., "Association of the TGF-α receptor genes with abdominal aortic aneurysm," European Journal of Human Genetics, vol. 18, no. 2, pp. 240-244, 2010.
11. S. Kontusaari, G. Tromp, H. Kuivaniemi, R. L. Ladda, and D. J. Prockop, "Inheritance of an RNA splicing mutation (G+ 1 IVS20) in the type III procollagen gene (COL3A1) in a family having aortic aneurysms and easy bruisability: phenotypic overlap between familial arterial aneurysms and Ehlers-Danlos syndrome type IV," American Journal of Human Genetics, vol. 47, no. 1, pp. 112-120, 1990.
12. L. B. Smith, P. W. F. Hadoke, E. Dyer et al., "Haploinsufciency of the murine Col3a1 locus causes aortic dissection: a novel model of the vascular type of EhlersDanlos syndrome," Cardiovascular Research, vol. 90, no. 1, pp. 182-190, 2011.
13. J. Faugeroux, H. Nematalla, W. Li et al., "Angiotensin II promotes thoracic aortic dissections and ruptures in Col3a1 haploinsufcient mice," Hypertension, vol. 62, no. 1, pp. 203-208, 2013.
14. T. Ogata, H. Shibamura, G. Tromp et al., "Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms," Journal of Vascular Surgery, vol. 41, no. 6, pp. 1036-1042, 2005.
15. H. Pannu, V. Tran-Fadulu, C. L. Papke et al., "MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II," Human Molecular Genetics, vol. 16, no. 20, pp. 2453-2462, 2007.
16. L. Zhu, R. Vranckx, P. K. Van Kien et al., "Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus," Nature Genetics, vol. 38, no. 3, pp. 343-349, 2006.
17. D.-C. Guo, H. Pannu, V. Tran-Fadulu et al., "Mutations in smooth muscle α-actin (ACTA2) lead to thoracic aortic aneurysms and dissections," Nature Genetics, vol. 39, no. 12, pp. 1488-1493, 2007.
18. D.-C. Guo, C. L. Papke, V. Tran-Fadulu et al., "Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease," The American Journal of Human Genetics, vol. 84, no. 5, pp. 617-627, 2009.
19. D.-C. Guo, E. S. Regalado, L. Gong et al., "LOX mutations predispose to thoracic aortic aneurysms and dissections," Circulation Research, vol. 118, no. 6, pp. 928-934, 2016.
20. D.-C. Guo, L. Gong, E. S. Regalado et al., "MAT2A mutations predispose individuals to thoracic aortic aneurysms," American Journal of Human Genetics, vol. 96, no. 1, pp. 170-177, 2015.
21. E. S. Regalado, D.-C. Guo, C. Villamizar et al., "Exome sequencing identifes SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms," Circulation Research, vol. 109, no. 6, pp. 680-686, 2011.
22. I. M. B. H. Van De Laar, R. A. Oldenburg, G. Pals et al., "Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis," Nature Genetics, vol. 43, no. 2, pp. 121-126, 2011.
23. I. S. Lantinga-van Leeuwen, J. G. Dauwerse, H. J. Baelde et al., "Lowering of Pkd1 expression is sufcient to cause polycystic kidney disease," Human Molecular Genetics, vol. 13, no. 24, pp. 3069-3077, 2004.
24. R. Torra, C. Nicolau, C. Badenas et al., "Abdominal aortic aneurysms and autosomal dominant polycystic kidney disease," Journal of the American Society of Nephrology, vol. 7, no. 11, pp. 2483-2486, 1996.
25. J. M. Friedman, J. Arbiter, J. A. Epstein et al., "Cardiovascular disease in neurofbromatosis 1: report of the NF1 Cardiovascular Task Force," Genetics in Medicine, vol. 4, no. 3, pp. 105-111, 2002.
26. B. K. Stansfeld, W. K. Bessler, R. Mali et al., "Ras-mek-erk signaling regulates Nf1 heterozygous neointima formation," American Journal of Pathology, vol. 184, no. 1, pp. 79-85, 2014.
27. F. Li, B. D. Downing, L. C. Smiley et al., "Neurofbromin-defcient myeloid cells are critical mediators of aneurysm formation in vivo," Circulation, vol. 129, no. 11, pp. 1213-1224, 2014.
28. H. Yanagisawa, E. C. Davist, B. C. Starcher et al., "Fibulin-5 is an elastin-binding protein essential for elastic fbre development in vivo," Nature, vol. 415, no. 6868, pp. 168-171, 2002.
29. M. Orriols, S. Varona, I. Martí-Pàmies et al., "Down-regulation of Fibulin-5 is associated with aortic dilation: role of infamma-tion and epigenetics," Cardiovascular Research, vol. 110, no. 3, pp. 431-442, 2016.
30. S. A. Badger, C. V. Soong, M. E. O'Donnell, M. A. Sharif, R. R. Makar, and A. E. Hughes, "Common polymorphisms of Fibulin-5 and the risk of abdominal aortic aneurysm development," Vascular Medicine, vol. 15, no. 2, pp. 113-117, 2010.
31. I. Hinterseher, H. Bergert, E. Kuhlisch et al., "Matrix metal-loproteinase 2 polymorphisms in a caucasian population with abdominal aortic aneurysm," Journal of Surgical Research, vol. 133, no. 2, pp. 121-128, 2006.
32. L. Smallwood, R. Allcock, F. Van Bockxmeer et al., "Polymorphisms of the matrix metalloproteinase 9 gene and abdominal aortic aneurysm," British Journal of Surgery, vol. 95, no. 10, pp. 1239-1244, 2008.
33. G. M. Longo, S. J. Buda, N. Fiotta et al., "MMP-12 has a role in abdominal aortic aneurysms in mice," Surgery, vol. 137, no. 4, pp. 457-562, 2005.
34. J. Deguara, K. G. Burnand, J. Berg et al., "An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms," Human Molecular Genetics, vol. 16, no. 24, pp. 3002-3007, 2007.
35. N. Lamblin, C. Bauters, X. Hermant, J.-M. Lablanche, N. Helbecque, and P. Amouyel, "Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease," Journal of the American College of Cardiology, vol. 40, no. 1, pp. 43-48, 2002.
36. M. J. Bown, G. T. Jones, S. C. Harrison et al., "Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1," The American Journal of Human Genetics, vol. 89, no. 5, pp. 619-627, 2011.
37. D. T. Bradley, A. E. Hughes, S. A. Badger et al., "A variant in LDLR is associated with abdominal aortic aneurysm," Circulation: Cardiovascular Genetics, vol. 6, no. 5, pp. 498-504, 2013.
38. L. U. Gerdes, J. S. Lindholt, S. Vammen, E. W. Henneberg, and H. Fasting, "Apolipoprotein E genotype is associated with differential expansion rates of small abdominal aortic aneurysms," British Journal of Surgery, vol. 87, no. 6, pp. 760-765, 2000.
39. J. W. Cornwall, R. S. Green, J. C. Nielsen, and B. D. Gelb, "Frequency of aortic dilation in Noonan syndrome," The American Journal of Cardiology, vol. 113, no. 2, pp. 368-371, 2014.
40. M. E. Lindsay and H. C. Dietz, "Lessons on the pathogenesis of aneurysm from heritable conditions," Nature, vol. 473, no. 7347, pp. 308-316, 2011.
41. R. Purnell, I. Williams, U. Von Oppell, and A. Wood, "Giant aneurysms of the sinuses of Valsalva and aortic regurgitation in a patient with Noonan's syndrome," European Journal of Cardio-Toracic Surgery, vol. 28, no. 2, pp. 346-348, 2005.
42. H. Cao, X. Hu, Q. Zhang et al., "Hyperhomocysteinaemia, low folate concentrations and MTHFR C677T mutation in abdominal aortic aneurysm," Vasa-European Journal of Vascular Medicine, vol. 43, no. 3, pp. 181-188, 2014.
43. J. Liu, X. Jia, H. Li et al., "Association between MTHFR C677T polymorphism and abdominal aortic aneurysm risk," Medicine, vol. 95, no. 36, Article ID e4793, 2016.
44. F. Ferrara, S. Novo, S. Grimaudo et al., "Methylenetetrahydro-folate reductase mutation in subjects with abdominal aortic aneurysm subdivided for age," Clinical Hemorheology and Microcirculation, vol. 34, no. 3, pp. 421-426, 2006.
45. C. M. Bhamidipati, C. A. Whatling, G. S. Mehta et al., "5-Lipoxygenase pathway in experimental abdominal aortic aneurysms," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 34, no. 12, pp. 2669-2678, 2014.
46. L. Zhao, M. P. W. Moos, R. Gräbner et al., "Te 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm," Nature Medicine, vol. 10, no. 9, pp. 966-973, 2004.
47. E. J. Ryer, K. E. Ronning, R. Erdman et al., "Te potential role of DNA methylation in abdominal aortic aneurysms," International Journal of Molecular Sciences, vol. 16, no. 5, pp. 11259-11275, 2015.
48. L. Maegdefessel, J. Azuma, R. Toh et al., "MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion," Science Translational Medicine, vol. 4, no. 122, Article ID 122ra22, 2012.
49. L. Maegdefessel, J. Azuma, R. Toh et al., "Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development," The Journal of Clinical Investigation, vol. 122, no. 2, pp. 497-506, 2012.
50. D. R. Merk, J. T. Chin, B. A. Dake et al., "miR-29b participates in early aneurysm development in Marfan syndrome," Circulation Research, vol. 110, no. 2, pp. 312-324, 2012.
51. S. S. Chaudhry, S. A. Cain, A. Morgan, S. L. Dallas, C. A. Shuttleworth, and C. M. Kielty, "Fibrillin-1 regulates the bioavailability of TGFα1," The Journal of Cell Biology, vol. 176, no. 3, pp. 355-367, 2007.
52. F. Ramirez, L. Y. Sakai, D. B. Rifin, and H. C. Dietz, "Extracellular microfbrils in development and disease," Cellular and Molecular Life Sciences, vol. 64, no. 18, pp. 2437-2446, 2007.
53. B. L. Loeys, U. Schwarze, T. Holm et al., "Aneurysm syndromes caused by mutations in the TGF-α receptor," New England Journal of Medicine, vol. 355, no. 8, pp. 788-798, 2006.
54. H. Pannu, V. Tran-Fadulu, and D. M. Milewicz, "Genetic basis of thoracic aortic aneurysms and aortic dissections," American Journal of Medical Genetics Part C: Seminars in Medical Genetics, vol. 139, no. 1, pp. 10-16, 2005.
55. H. Pannu, V. T. Fadulu, J. Chang et al., "Mutations in transforming growth factor-α receptor type II cause familial thoracic aortic aneurysms and dissections," Circulation, vol. 112, no. 4, pp. 513-520, 2005.
56. D.-C. Guo, E. Regalado, D. E. Casteel et al., "Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections," American Journal of Human Genetics, vol. 93, no. 2, pp. 398-404, 2013.
57. D.-C. Guo, E. S. Regalado, C. Minn et al., "Familial thoracic aortic aneurysms and dissections identification of a novel locus for stable aneurysms with a low risk for progression to aortic dissection," Circulation: Cardiovascular Genetics, vol. 4, no. 1, pp. 36-42, 2011.
58. S.-Q. Kuang, O. Medina-Martinez, D.-C. Guo et al., "FOXE3 mutations predispose to thoracic aortic aneurysms and dissections," The Journal of Clinical Investigation, vol. 126, no. 3, pp. 948-961, 2016.
59. E. Regalado, S. Medrek, V. Tran-Fadulu et al., "Autoso-mal dominant inheritance of a predisposition to thoracic aortic aneurysms and dissections and intracranial saccular aneurysms," American Journal of Medical Genetics A, vol. 155, no. 9, pp. 2125-2130, 2011.
60. D. M. Milewicz and E. Regalado, "Toracic aortic aneurysms and aortic dissections," in GeneReviews®, R. A. Pagon, M. P. Adam, H. H. Ardinger et al., Eds., University of Washington, Seattle, Wash, USA, 1993.
61. D. M. Milewicz and E. S. Regalado, "Use of genetics for personalized management of heritable thoracic aortic disease: how do we get there?" The Journal of Toracic and Cardiovascular Surgery, vol. 149, no. 2, pp. S3-S5, 2015.
62. A. B. Chapman, D. Rubinstein, R. Hughes et al., "Intracranial aneurysms in autosomal dominant polycystic kidney disease," The New England Journal of Medicine, vol. 327, no. 13, pp. 916-920,1992.
63. T. Ecder and R. W. Schrier, "Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease," Nature Reviews Nephrology, vol. 5, no. 4, pp. 221-228, 2009.
64. S. Hassane, N. Claij, I. S. Lantinga-van Leeuwen et al., "Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 27, no. 10, pp. 2177-2183, 2007
65. I. Hinterseher, G. Tromp, and H. Kuivaniemi, "Genes and abdominal aortic aneurysm," Annals of Vascular Surgery, vol. 25, no. 3, pp. 388-412, 2011.
66. A. F. Baas, J. Medic, R. van't Slot et al., "Association study of single nucleotide polymorphisms on chromosome 19q13 with abdominal aortic aneurysm," Angiology, vol. 61, no. 3, pp. 243-247, 2010.
67. J. R. Elmore, M. A. Obmann, H. Kuivaniemi et al., "Identification of a genetic variant associated with abdominal aortic aneurysms on chromosome 3p12.3 by genome wide association," Journal of Vascular Surgery, vol. 49, no. 6, pp. 1525-1531, 2009.
68. S. Gretarsdottir, A. F. Baas, G Torleifsson et al., "Genome-wide association study identifes a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm," Nature Genetics, vol. 42, no. 8, pp. 692-697, 2010.
69. L. Faivre, G Collod-Beroud, B. Callewaert et al., "Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for marfan syndrome: further delineation of type 1 fbrillinopathies and focus on patients with an isolated major criterion," American Journal of Medical Genetics, Part A, vol. 149, no. 5, pp. 854-860, 2009.
70. B. Loeys, L. Van Maldergem, G. Mortier et al., "Homozygosity for a missense mutation in fbulin-5 (FBLN5) results in a severe form of cutis laxa," Human Molecular Genetics, vol. 11, no. 18, pp. 2113-2118, 2002.
71. C. L. Papke and H. Yanagisawa, "Fibulin-4 and fbulin-5 in elastogenesis and beyond: insights from mouse and human studies," Matrix Biology, vol. 37, pp. 142-149, 2014.
72. A. K. Ewart, C. A. Morris, D. Atkinson et al., "Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome," Nature Genetics, vol. 5, no. 1, pp. 11-16,1993.
73. J. E. Wagenseil, C. H. Ciliberto, R. H. Knutsen, M. A. Levy, A. Kovacs, and R. P. Mecham, "Te importance of elastin to aortic development in mice," American Journal of Physiology- Heart and Circulatory Physiology, vol. 299, no. 2, pp. H257-H264, 2010.
74. W.-H. Fan and M. J. Karnovsky, "Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells," The Journal of Biological Chemistry, vol. 277, no. 12, pp. 9800-9805, 2002.
75. G. M. Longo, W. Xiong, T. C. Greiner, Y. Zhao, N. Fiotti, and B. T. Baxter, "Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms," The Journal of Clinical Investigation, vol. 110, no. 5, pp. 625-632, 2002.
76. J. S. Matsumura and W. H. Pearce, "Infrarenal aortic aneurysms," The New England Journal of Medicine, vol. 336, no. 24, pp. 1756-1758, 1997.
77. N. Sakalihasan, P. Delvenne, B. V. Nusgens, R. Limet, and C. M. Lapiere, "Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms," Journal of Vascular Surgery, vol. 24, no. 1, pp. 127-133, 1996.
78. U. Schönbeck, F. Mach, G. K. Sukhova et al., "Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?" Circulation Research, vol. 81, no. 3, pp. 448-454, 1997.
79. N. A. Tamarina, W. D. McMillan, V. P. Shively, and W. H. Pearce, "Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta," Surgery, vol. 122, no. 2, pp. 264-272, 1997.
80. M. Folkesson, M. Kazi, C. Zhu et al., "Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms," Trombo-sis and Haemostasis, vol. 98, no. 2, pp. 427-433, 2007.
81. A. R. Tompson, F. Drenos, H. Hafez, and S. E. Humphries, "Candidate gene association studies in abdominal aortic aneurysm disease: a review and meta-analysis," European Journal of Vascular and Endovascular Surgery, vol. 35, no. 1, pp. 19-30, 2008.
82. E. R. Neptune, P. A. Frischmeyer, D. E. Arking et al., "Dysregula-tion of TGF-α activation contributes to pathogenesis in Marfan syndrome," Nature Genetics, vol. 33, no. 3, pp. 407-411, 2003.
83. E. Gillis, L. Van Laer, and B. L. Loeys, "Genetics of thoracic aortic aneurysm: at the crossroad of transforming growth factor-α signaling and vascular smooth muscle cell contractility," Circulation Research, vol. 113, no. 3, pp. 327-340, 2013.
84. J. P. Habashi, D. P. Judge, T. M. Holm et al., "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome," Science, vol. 312, no. 5770, pp. 117-121, 2006.
85. J. P. Habashi, J. J. Doyle, T. M. Holm et al., "Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism," Science, vol. 332, no. 6027, pp. 361-365, 2011.
86. T. M. Holm, J. P. Habashi, J. J. Doyle et al., "Noncanonical TGFα signaling contributes to aortic aneurysm progression in marfan syndrome mice," Science, vol. 332, no. 6027, pp. 358-361, 2011.
87. Y. Wang, S. Krishna, P. J. Walker, P. Norman, and J. Golledge, "Transforming growth factor-α and abdominal aortic aneurysms," Cardiovascular Pathology, vol. 22, no. 2, pp. 126-132, 2013.
88. Y. Wang, H. Ait-Oufella, O. Herbin et al., "TGF-α activity protects against infammatory aortic aneurysm progression and complications in angiotensin II-infused mice," The Journal of Clinical Investigation, vol. 120, no. 2, pp. 422-432, 2010.
89. F. Gao, P. Chambon, S. Ofermanns et al., "Disruption of TGF-α signaling in smooth muscle cell prevents elastase-induced abdominal aortic aneurysm," Biochemical and Biophysical Research Communications, vol. 454, no. 1, pp. 137-143, 2014.
90. H. Ait-Oufella, Y. Wang, O. Herbin, A. Tedgui, and Z. Mallat, "Role of TGFα in a model of abdominal aortic aneurysm in mice," M édecine Science, vol. 26, no. 10, pp. 795-797, 2010.
91. L. Lucarini, E. Sticchi, F. Sof et al., "ACE and TGFBR1 genes interact in infuencing the susceptibility to abdominal aortic aneurysm," Atherosclerosis, vol. 202, no. 1, pp. 205-210, 2009.
92. A. Siegert, E. Ritz, S. Orth, and J. Wagner, "Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-α1 in vascular smooth muscle," Journal of Molecular Medicine, vol. 77, no. 5, pp. 437-445, 1999.
93. N. Fukuda, W.-Y. Hu, A. Kubo et al., "Angiotensin II upregulates transforming growth factor-α type I receptor on rat vascular smooth muscle cells," American Journal of Hypertension, vol. 13, no. 2, pp. 191-198, 2000.
94. L. Zhu, D. Bonnet, M. Boussion, B. Vedie, D. Sidi, and X. Jeunemaitre, "Investigation of the MYH11 gene in sporadic patients with an isolated persistently patent arterial duct," Cardiology in the Young, vol. 17, no. 6, pp. 666-672, 2007.
95. A. K. Soutar and R. P. Naoumova, "Mechanisms of disease: genetic causes of familial hypercholesterolemia," Nature Clinical Practice Cardiovascular Medicine, vol. 4, no. 4, pp. 214-225, 2007.
96. M. J. Bown, "Genomic insights into abdominal aortic aneu-rysms," Annals of the Royal College of Surgeons of England, vol. 96, no. 6, pp. 405-414, 2014.
97. D. C. Ewbank, "Te APOE gene and diferences in life expectancy in Europe," The Journals of Gerontology-Series A Biological Sciences and Medical Sciences, vol. 59, no. 1, pp. 16-20, 2004.
98. L. U. Gerdes, B. Jeune, K. A. Ranberg, H. Nybo, and J. W. Vaupel, "Estimation of apolipoprotein E genotype-specifc relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoprotein E gene is a 'frailty gene,' not a 'longevity gene'," Genetic Epidemiology, vol. 19, no. 3, pp. 202-210, 2000.
99. R. Jacobsen, T. Martinussen, L. Christiansen et al., "Increased effect of the ApoE gene on survival at advanced age in healthy and long-lived Danes: two nationwide cohort studies," Aging Cell, vol. 9, no. 6, pp. 1004-1009, 2010.
100. D. Viskochil, A. M. Buchberg, G. Xu et al., "Deletions and a translocation interrupt a cloned gene at the neurofbromatosis type 1 locus," Cell, vol. 62, no. 1, pp. 187-192, 1990.
101. W. K. Bessler, F. Z. Hudson, H. Zhang et al., "Neurofbromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans," Free Radical Biology & Medicine, vol. 97, pp. 212-222, 2016.
102. +/- mono-cytes/macrophages induce neointima formation via CCR2 activation," Human Molecular Genetics, vol. 25, no. 6, pp. 1129-1139, 2016.
103. B. K. Stansfeld, W. K. Bessler, R. Mali et al., "Heterozygous inac-tivation of the NF1 gene in myeloid cells enhances neointima formation via a rosuvastatin-sensitive cellular pathway," Human Molecular Genetics, vol. 22, no. 5, pp. 977-988, 2013.
104. J. E. Allanson, M. Upadhyaya, G. H. Watson et al., "Watson syndrome: is it a subtype of type 1 neurofbromatosis?" Journal of Medical Genetics, vol. 28, no. 11, pp. 752-756, 1991.
105. G. S. Oderich, T. M. Sullivan, T. C. Bower et al., "Vascular abnormalities in patients with neurofbromatosis syndrome type I: clinical spectrum, management, and results," Journal of Vascular Surgery, vol. 46, no. 3, pp. 475-484, 2007.
106. D. Rea, J. F. Brandsema, D. Armstrong et al., "Cerebral arteri-opathy in children with neurofbromatosis type 1," Pediatrics, vol. 124, no. 3, pp. e476-e483, 2009.
107. E. Fossali, E. Signorini, R. C. Intermite et al., "Renovascular disease and hypertension in children with neurofbromatosis," Pediatric Nephrology, vol. 14, no. 8-9, pp. 806-810, 2000.
108. M. Henkemeyer, D. J. Rossi, D. P. Holmyard et al., "Vascular system defects and neuronal apoptosis in mice lacking Ras GTPase-activating protein," Nature, vol. 377, no. 6551, pp. 695-701, 1995.
109. T. L. Rosser, G. Vezina, and R. J. Packer, "Cerebrovascular abnormalities in a population of children with neurofbromato-sis type 1," Neurology, vol. 64, no. 3, pp. 553-555, 2005.
110. S. A. Lemaire, X. Wang, J. A. Wilks et al., "Matrix metal-loproteinases in ascending aortic aneurysms: bicuspid versus trileafet aortic valves," Journal of Surgical Research, vol. 123, no. 1, pp. 40-48, 2005.
111. W. D. McMillan, N. A. Tamarina, M. Cipollone, D. A. Johnson, M. A. Parker, and W. H. Pearce, "Size matters: the relationship between MMP-9 expression and aortic diameter," Circulation, vol. 96, no. 7, pp. 2228-2232, 1997.
112. M. Shen, J. Lee, R. Basu et al., "Divergent roles of matrix met-alloproteinase 2 in pathogenesis of thoracic aortic aneurysm," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 35, no. 4, pp. 888-898, 2015.
113. S. Zhang, B. Zhong, M. Chen et al., "Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells," International Journal of Cancer, vol. 134, no. 7, pp. 1583-1594, 2014.
114. P. Stenvinkel, M. Karimi, S. Johansson et al., "Impact of infammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?" Journal of Internal Medicine, vol. 261, no. 5, pp. 488-499, 2007.
115. N. R. Fuggle, F. A. Howe, R. Allen, and N. Sofat, "New insights into the impact of neuro-infammation in rheumatoid arthritis," Frontiers in Neuroscience, vol. 8, article 357, 2014.
116. I. T. Pereira, E. A. S. Ramos, E. T. Costa et al., "Fibronectin afects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines," PLoS ONE, vol. 9, no. 9, Article ID e105806, 2014.
117. M. Ailenberg and M. Silverman, "Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression," Biochemical and Biophysical Research Communications, vol. 298, no. 1, pp. 110-115, 2002.
118. C. Yuan, L. Zhang, Y. Gao, D. Peng, J. Liu, and Y. Cai, "DNA demethylation at the promoter region enhances the expression of MMP-9 in ectopic endometrial stromal cells of endometriosis," Chinese Journal of Cellular and Molecular Immunology, vol. 30, no. 12, pp. 1258-1261, 2014.
119. S. Nozell, Z. Ma, C. Wilson, R. Shah, and E. N. Benveniste, "Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression," The Journal of Biological Chemistry, vol. 279, no. 37, pp. 38577-38589, 2004.
120. C. Yan, H. Wang, Y. Toh, and D. D. Boyd, "Repression of 92-kDa type IV collagenase expression by MTA1 is mediated through direct interactions with the promoter via a mechanism, which is both dependent on and independent of histone deacetylation," The Journal of Biological Chemistry, vol. 278, no. 4, pp. 2309-2316, 2003.
121. M. Galán, S. Varona, M. Orriols et al., "Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors," Disease Models and Mechanisms, vol. 9, no. 5, pp. 541-552, 2016.
122. A. Vinh, T. A. Gaspari, H. B. Liu, L. F. Dousha, R. E. Wid-dop, and A. E. Dear, "A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-defcient mice," Journal of Vascular Research, vol. 45, no. 2, pp. 143-152, 2008.
123. T. Brunelli, D. Prisco, S. Fedi et al., "High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm," Journal of Vascular Surgery, vol. 32, no. 3, pp. 531-536, 2000.
124. J. Liu, S. W. Zuo, Y. Li et al., "Hyperhomocysteinaemia is an independent risk factor of abdominal aortic aneurysm in a Chinese Han population," Scientific Reports, vol. 6, Article ID 17966, 2016.
125. K.J.Halazun,K.A.Bofin,S.Asthana,C.Evans,M.Henderson, and J. I. Spark, "Hyperhomocysteinaemia is associated with the rate of abdominal aortic aneurysm expansion," European Journal of Vascular and Endovascular Surgery, vol. 33, no. 4, pp. 391-394, 2007.
126. S. M. Krishna, A. Dear, J. M. Craig, P. E. Norman, and J. Golledge, "Te potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation," Atherosclerosis, vol. 228, no. 2, pp. 295-305, 2013.
127. B. J. Toghill, A. Saratzis, S. C. Harrison, A. R. Verissimo, E. B. Mallon, and M. J. Bown, "Te potential role of DNA methylation in the pathogenesis of abdominal aortic aneurysm," Atherosclerosis, vol. 241, no. 1, pp. 121-129, 2015.
128. Z. Chen, A. C. Karaplis, S. L. Ackerman et al., "Mice def-cient in methylenetetrahydrofolate reductase exhibit hyper-homocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition," Human Molecular Genetics, vol. 10, no. 5, pp. 433-443, 2001.
129. K. W. K. Lee and Z. Pausova, "Cigarette smoking and DNA methylation," Frontiers in Genetics, vol. 4, article no. 132, 2013.
130. L. P. Breitling, R. Yang, B. Korn, B. Burwinkel, and H. Brenner, "Tobacco-smoking-related differential DNA methylation: 27K discovery and replication," American Journal of Human Genetics, vol. 88, no. 4, pp. 450-457, 2011.
131. B. A. Mercer, A. M. Wallace, C. E. Brinckerhof, and J. M. D'Armiento, "Identification of a cigarette smoke-responsive region in the distal MMP-1 promoter," American Journal of Respiratory Cell and Molecular Biology, vol. 40, no. 1, pp. 4-12, 2009.
132. R. Satta, E. Maloku, A. Zhubi et al., "Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 42, pp. 16356-16361, 2008.
133. R. Joehanes, A. C. Just, R. E. Marioni et al., "Epigenetic signatures of cigarette smoking," Circulation: Cardiovascular Genetics, vol. 9, no. 5, pp. 436-447, 2016.
134. L. G. Tsaprouni, T.-P. Yang, J. Bell et al., "Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation," Epigenetics, vol. 9, no. 10, pp. 1382-1396, 2014.
135. S. Ambatipudi, C. Cuenin, H. Hernandez-Vargas et al., "Tobacco smoking-associated genome-wide DNA methylation changes in the EPIC study," Epigenomics, vol. 8, no. 5, pp. 599-618, 2016.
136. M. M. Monick, S. R. H. Beach, J. Plume et al., "Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers," American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 159, no. 2, pp. 141-151, 2012.
137. J. Sandoval, H. A. Heyn, S. Moran et al., "Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome," Epigenetics, vol. 6, no. 6, pp. 692-702, 2011.
138. U. P. Kelavkar, N. S. Harya, J. Hutzley et al., "DNA methy-lation paradigm shif: 15-lipoxygenase-1 upregulation in pro-static intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation," Prostaglandins and Other Lipid Mediators, vol. 82, no. 1-4, pp. 185-197, 2007.
139. H. Takagi and T. Umemoto, "Smoking promotes pathogenesis of aortic aneurysm through the 5-lipoxygenase pathway," Medical Hypotheses, vol. 64, no. 6, pp. 1117-1119, 2005.
140. P. A. Jones, S. M. Taylor, and V. L. Wilson, "Inhibition of DNA methylation by 5-azacytidine," Recent Results in Cancer Research, vol. 84, pp. 202-211, 1983.
141. V. L. Wilson and P. A. Jones, "DNA methylation decreases in aging but not in immortal cells," Science, vol. 220, no. 4601, pp. 1055-1057, 1983.
142. M. Jung and G. P. Pfeifer, "Aging and DNA methylation," BMC Biology, vol. 13, article 7, 2015.
143. M. O. Hiltunen, M. P. Turunen, T. P. Häkkinen et al., "DNA hypomethylation and methyltransferase expression in atherosclerotic lesions," Vascular Medicine, vol. 7, no. 1, pp. 5-11, 2002.
144. X. Lin, W. Zhang, Q. Lu et al., "Efect of MTHFR gene polymorphism impact on atherosclerosis via genome-wide methylation," Medical Science Monitor, vol. 22, pp. 341-345, 2016.
145. S. B. Baylin, J. G. Herman, J. R. Graf, P. M. Vertino, and J. P. Issa, "Alterations in DNA methylation: a fundamental aspect of neoplasia," Advances in Cancer Research, vol. 72, pp. 141-169, 1998.
146. M. El-Sammak, M. Kandil, S. El-Hifni, R. Hosni, and M. Ragab, "Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofo-late reductase gene in selected Egyptian subjects," International Journal of Medical Sciences, vol. 1, no. 3, pp. 181-192, 2004.
147. L. D. Spotila, P. F. Jacques, P. B. Berger, K. V. Ballman, R. C. Ellison, and R. Rozen, "Age Dependence of the Infuence of Methylenetetrahydrofolate Reductase Genotype on Plasma Homocysteine Level," American Journal of Epidemiology, vol. 158, no. 9, pp. 871-877, 2003.
148. A. Straßburg, C. Krems, P. M. Lührmann, B. Hartmann, and M. Neuhäuser-Berthold, "Efect of age on plasma homocysteine concentrations in young and elderly subjects considering serum vitamin concentrations and diferent lifestyle factors," International Journal for Vitamin and Nutrition Research, vol. 74, no. 2, pp. 129-136, 2004.
149. S. Horvath, "DNA methylation age of human tissues and cell types," Genome Biology, vol. 14, no. 10, article R115, 2013.
150. S. Kochanek, A. Radbruch, H. Tesch, D. Renz, and W. Doerfer, "DNA methylation profles in the human genes for tumor necrosis factors α and α in subpopulations of leukocytes and in leukemias," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 13, pp. 5759-5763, 1991.
151. Z. H. Liu, L. L. Chen, X. L. Deng et al., "Methylation status of CpG sites in the MCP-1 promoter is correlated to serum MCP-1 in type 2 diabetes," Journal of Endocrinological Investigation, vol. 35, no. 6, pp. 585-589, 2012.
152. K. E. Sullivan, A. B. M. Reddy, K. Dietzmann et al., "Epigenetic regulation of tumor necrosis factor alpha," Molecular and Cellular Biology, vol. 27, no. 14, pp. 5147-5160, 2007.
153. J. Wang, Y. Jiang, A. Yang et al., "Hyperhomocysteinemia-induced monocyte chemoattractant protein-1 promoter DNA methylation by nuclear factor-αB/DNA methyltransferase 1 in apolipoprotein E-defcient mice," BioResearch Open Access, vol. 2, no. 2, pp. 118-127, 2013.
154. I. Wessels, D. Fleischer, L. Rink, and P. Uciechowski, "Changes in chromatin structure and methylation of the human interleukin-1α gene during monopoiesis," Immunology, vol. 130, no. 3, pp. 410-417, 2010.
155. J. Makino, R. Ogasawara, T. Kamiya et al., "Royal Jelly constituents increase the expression of extracellular superoxide dismutase through histone acetylation in monocytic THP-1 cells," Journal of Natural Products, vol. 79, no. 4, pp. 1137-1143, 2016.
156. N. N. Soe, M. Sowden, P. Baskaran et al., "Acetylation of cyclophilin A is required for its secretion and vascular cell activation," Cardiovascular Research, vol. 101, no. 3, pp. 444-453, 2014.
157. F. M. Moodie, J. A. Marwick, C. S. Anderson et al., "Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-αB activation and proinfammatory cytokine release in alveolar epithelial cells," The FASEB Journal, vol. 18, no. 15, pp. 1897-1899, 2004.
158. D. Pons, F. R. de Vries, P. J. van den Elsen, B. T. Heijmans, P. H. A. Quax, and J. W. Jukema, "Epigenetic histone acetylation modifers in vascular remodelling: new targets for therapy in cardiovascular disease," European Heart Journal, vol. 30, no. 3, pp. 266-277, 2009.
159. I. Hinterseher, R. Erdman, J. R. Elmore et al., "Novel pathways in the pathobiology of human abdominal aortic aneurysms," Pathobiology, vol. 80, no. 1, pp. 1-10, 2013.
160. M. C. Pahl, K. Derr, G. Gäbel et al., "MicroRNA expression signature in human abdominal aortic aneurysms," BMC Medical Genomics, vol. 5, article 25, 2012.
161. K. Kin, S. Miyagawa, S. Fukushima et al., "Tissue- and plasma-specifc MicroRNA signatures for atherosclerotic abdominal aortic aneurysm," Journal of the American Heart Association, vol. 1, no. 5, Article ID e000745, 2012.
162. S.-G. Sun, B. Zheng, M. Han et al., "MiR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation," EMBO Reports, vol. 12, no. 1, pp. 56-62, 2011.
163. M. Adam, U. Raaz, J. M. Spin, and P. S. Tsao, "MicroRNAs in abdominal aortic aneurysm," Current Vascular Pharmacology, vol. 13, no. 3, pp. 280-290, 2015.
164. W. Zhang, T. Shang, C. Huang et al., "Plasma microRNAs serve as potential biomarkers for abdominal aortic aneurysm," Clinical Biochemistry, vol. 48, no. 15, pp. 988-992, 2015.
165. P. W. Stather, N. Sylvius, D. A. Sidlof et al., "Identification of microRNAs associated with abdominal aortic aneurysms and peripheral arterial disease," British Journal of Surgery, vol. 102, no. 7, pp. 755-766, 2015.
166. R. A. Boon, T. Seeger, S. Heydt et al., "MicroRNA-29 in aortic dilation: implications for aneurysm formation," Circulation Research, vol. 109, no. 10, pp. 1115-1119, 2011.
167. L. Maegdefessel, J. M. Spin, U. Raaz et al., "miR-24 limits aortic vascular infammation and murine abdominal aneurysm development," Nature Communications, vol. 5, p. 5214, 2014.
168. C. W. Kim, S. Kumar, D. J. Son, I.-H. Jang, K. K. Griendling, and H. Jo, "Prevention of abdominal aortic aneurysm by anti-microRNA-712 or anti-microRNA-205 in angiotensin II-infused mice," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 34, no. 7, pp. 1412-1421, 2014.